ASIX Stock Analysis: AdvanSix | NYSE
Chemicals | NYSE, USA | Market Cap: 439m USD | 12M Return: -3.9% | US00773T1016 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.95M
Qual. Beats: 0
Rev. Trend: 54.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AdvanSix Inc. (NYSE: ASIX) is an integrated chemistry company that manufactures and sells polymer resins, primarily Nylon 6, a synthetic material used in fibers, filaments, engineered plastics, and films. Beyond Nylon 6, the company produces caprolactam (a key feedstock for polymer resins), ammonium sulfate fertilizers sold through distributors and farm cooperatives, and acetone used in adhesives, paints, coatings, and solvents. Its portfolio also includes a range of intermediate chemicals such as phenol, alpha-methylstyrene, cyclohexanone, and specialty amines, marketed under brand names including Aegis, Sulf-N, Nadone, Naxol, and EZ-Blox. The company distributes its products both directly and through third-party distributors.
As a commodity chemicals producer in the Materials sector, AdvanSix is vertically integrated across the nylon value chain-from caprolactam production to finished resin-giving it control over multiple stages of the manufacturing process. Headquartered in Parsippany, New Jersey, the company was incorporated in 2016 and operates as a small-cap entity with a market capitalization of $427 million.
- Nylon 6 and caprolactam pricing swings drive core margins
- Ammonium sulfate fertilizer demand shifts with global crop markets
- Benzene feedstock and energy costs pressure acetone profitability
| Net Income: -22.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.31 > 1.0 |
| NWC/Revenue: 4.42% < 20% (prev 8.09%; Δ -3.67% < -1%) |
| CFO/TA 0.06 > 3% & CFO 106.4m > Net Income -22.6m |
| Net Debt (537.0m) to EBITDA (58.8m): 9.13 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.1m) vs 12m ago -0.63% < -2% |
| Gross Margin: 16.56% > 18% (prev 9.98%; Δ 6.58% > 0.5%) |
| Asset Turnover: 96.04% > 50% (prev 88.33%; Δ 7.71% > 0%) |
| Interest Coverage Ratio: -1.83 > 6 (EBIT TTM -21.0m / Interest Expense TTM 11.4m) |
| A: 0.04 (Total Current Assets 435.0m - Total Current Liabilities 363.6m) / Total Assets 1.68b |
| B: 0.38 (Retained Earnings 629.6m / Total Assets 1.68b) |
| C: -0.01 (EBIT TTM -21.0m / Avg Total Assets 1.68b) |
| D: 0.88 (Book Value of Equity 785.4m / Total Liabilities 892.1m) |
| Altman-Z'' = 2.34 = BBB |
| DSRI: 0.86 (Receivables 193.4m/208.2m, Revenue 1.62b/1.49b) |
| GMI: 0.60 (GM 9.98% / 16.56%) |
| AQI: 1.04 (AQ_t 0.08 / AQ_t-1 0.08) |
| SGI: 1.08 (Revenue 1.62b / 1.49b) |
| TATA: -0.08 (NI -22.6m - CFO 106.4m) / TA 1.68b) |
| Beneish M = -3.43 (Cap -4..+1) = AA |
As of November 08, 2026, the stock is trading at USD 16.82 with a total of 379,586 shares traded. Over the past week, the price has changed by +9.51%, over one month by +0.72%, over three months by -15.68% and over the past year by -3.90%.
Current recommended Stop Loss: 15.40 (which is 8.4% or 2.6 ATR below the current price).
AdvanSix has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ASIX.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20 | 18.9% |
P/S = 0.2714
P/B = 0.5585
Revenue TTM = 1.62b USD
EBIT TTM = -21.0m USD
EBITDA TTM = 58.8m USD
Long Term Debt = 215.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 44.2m USD (from shortTermDebt, last quarter)
Debt = 559.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 148.9m
Net Debt = 537.0m USD (calculated: Debt 559.5m - CCE 22.6m)
Enterprise Value = 975.5m USD (438.6m + Debt 559.5m - CCE 22.6m)
Interest Coverage Ratio = -1.83 (Ebit TTM -21.0m / Interest Expense TTM 11.4m)
EV/FCF = 44.05x (Enterprise Value 975.5m / FCF TTM 22.1m)
FCF Yield = 2.27% (FCF TTM 22.1m / Enterprise Value 975.5m)
FCF Margin = 1.37% (FCF TTM 22.1m / Revenue TTM 1.62b)
Net Margin = -1.40% (Net Income TTM -22.6m / Revenue TTM 1.62b)
Gross Margin = 16.56% ((Revenue TTM 1.62b - Cost of Revenue TTM 1.35b) / Revenue TTM)
Gross Margin QoQ = none% (prev 7.38%)
Tobins Q-Ratio = 0.58 (Enterprise Value 975.5m / Total Assets 1.68b)
Interest Expense / Debt = 2.04% (Interest Expense 11.4m / Debt 559.5m)
Taxrate = 9.45% (5.14m / 54.4m)
NOPAT = -19.0m (EBIT -21.0m * (1 - 9.45%)) [loss with tax shield]
Current Ratio = 1.20 (Total Current Assets 435.0m / Total Current Liabilities 363.6m)
Debt / Equity = 0.71 (Debt 559.5m / totalStockholderEquity, last quarter 785.4m)
Debt / EBITDA = 9.13 (Net Debt 537.0m / EBITDA 58.8m)
Debt / FCF = 24.25 (Net Debt 537.0m / FCF TTM 22.1m)
Total Stockholder Equity = 798.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.35% (Net Income -22.6m / Total Assets 1.68b)
RoE = -2.84% (Net Income TTM -22.6m / Total Stockholder Equity 798.5m)
RoCE = -2.07% (EBIT -21.0m / Capital Employed (Equity 798.5m + L.T.Debt 215.0m))
RoIC = -1.42% (negative operating profit) (NOPAT -19.0m / Invested Capital 1.34b)
WACC = 4.51% (E(438.6m)/V(998.1m) * Re(7.91%) + D(559.5m)/V(998.1m) * Rd(2.04%) * (1-Tc(0.09)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -1.92 | Cagr: -0.12%
[DCF] Terminal Value 77.97% ; FCFF base≈13.3m ; Y1≈15.3m ; Y5≈22.5m
[DCF] Fair Price = N/A (negative equity: EV 338.4m - Net Debt 537.0m = -198.6m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.78 | # QB: 0
Revenue Correlation: 54.07 | Revenue CAGR: 1.58% | SUE: 0.01 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.18 | Chg30d=-87.11% | Revisions=+0% | GrowthEPS=-91.9% | GrowthRev=+9.9%
EPS next Year (2027-12-31): EPS=2.38 | Chg30d=-18.46% | Revisions=-40% | GrowthEPS=+1189.2% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -40% (up=0, down=2)